SEC Comment Letter for Mereo BioPharma Group plc (MREO) (CIK 0001719714) (MREO) — May 20, 2024
Mereo BioPharma Group plc (MREO) (CIK 0001719714)
Date: May 20, 2024 · CIK: 0001719714 · Accession: 0000000000-24-005834
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279433
Letter
United States securities and exchange commission logo May 20, 2024 Denise Scots-Knight Chief Executive Officer Mereo BioPharma Group plc One Cavendish Place, 4th Floor London, W1G 0QF United Kingdom Re:Mereo BioPharma Group plc Registration Statement on Form S-3 Filed May 15, 2024 File No. 333-279433 Dear Denise Scots-Knight: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: David S. Bakst
Show Raw Text
United States securities and exchange commission logo
May 20, 2024
Denise Scots-Knight
Chief Executive Officer
Mereo BioPharma Group plc
One Cavendish Place, 4th Floor
London, W1G 0QF
United Kingdom
Re:Mereo BioPharma Group plc
Registration Statement on Form S-3
Filed May 15, 2024
File No. 333-279433
Dear Denise Scots-Knight:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: David S. Bakst